(Q34325329)

English

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation (English)

1 reference

Europe PubMed Central

1 August 2017

1 reference

based on heuristic

inferred from title

23

object named as

Richard Olsson

1 reference

Europe PubMed Central

1 August 2017

object named as

Mehdi Hamadani

1

0 references

Christopher Dandoy

object named as

Christopher Dandoy

36

0 references

Parameswaran Hari

object named as

Parameswaran N Hari

2

0 references

Robert Peter Gale

38

object named as

Robert Gale

1 reference

Europe PubMed Central

1 August 2017

Hillard M. Lazarus

20

object named as

Hillard M Lazarus

1 reference

Europe PubMed Central

1 August 2017

David G. Maloney

30

object named as

David G Maloney

1 reference

Europe PubMed Central

1 August 2017

28

object named as

Julie M Vose

1 reference

Europe PubMed Central

1 August 2017

25

object named as

David A Rizzieri

1 reference

Europe PubMed Central

1 August 2017

47

object named as

Harry C Schouten

1 reference

Europe PubMed Central

1 August 2017

35

object named as

Amanda Cashen

1 reference

Europe PubMed Central

1 August 2017

Edmund K Waller

50

object named as

Edmund K Waller

1 reference

Europe PubMed Central

1 August 2017

David J. Inwards-Breland

17

object named as

David J Inwards

1 reference

Europe PubMed Central

1 August 2017

32

object named as

Silvia Montoto

1 reference

Europe PubMed Central

1 August 2017

Jeanette Carreras

4

object named as

Jeanette Carreras

1 reference

Europe PubMed Central

1 August 2017

Mitchell S Cairo

44

object named as

Mitchell S Cairo

1 reference

Europe PubMed Central

1 August 2017

Timothy S Fenske

12

object named as

Timothy S Fenske

1 reference

Europe PubMed Central

1 August 2017

31

object named as

Sonali M Smith

1 reference

Europe PubMed Central

1 August 2017

33

object named as

Wael Saber

1 reference

Europe PubMed Central

1 August 2017

Rammurti T Kamble

18

object named as

Rammurti T Kamble

1 reference

Europe PubMed Central

1 August 2017

26

object named as

Bipin N Savani

1 reference

Europe PubMed Central

1 August 2017

29

object named as

Baldeep Wirk

1 reference

Europe PubMed Central

1 August 2017

Leona A Holmberg

16

object named as

Leona A Holmberg

1 reference

Europe PubMed Central

1 August 2017

Reinhold Munker

45

object named as

Reinhold Munker

1 reference

Europe PubMed Central

1 August 2017

Ernesto Rodriguez-Ayala

7

object named as

Ernesto Ayala

1 reference

Europe PubMed Central

1 August 2017

13

object named as

César O Freytes

1 reference

Europe PubMed Central

1 August 2017

43

object named as

Michael Lill

1 reference

Europe PubMed Central

1 August 2017

Taiga Nishihori

22

object named as

Taiga Nishihori

1 reference

Europe PubMed Central

1 August 2017

49

object named as

Patrick J Stiff

1 reference

Europe PubMed Central

1 August 2017

5

object named as

Görgün Akpek

1 reference

Europe PubMed Central

1 August 2017

6

object named as

Mahmoud D Aljurf

1 reference

Europe PubMed Central

1 August 2017

Veronika Bachanova

8

object named as

Veronika Bachanova

1 reference

Europe PubMed Central

1 August 2017

Siddhartha Ganguly

14

object named as

Siddhartha Ganguly

1 reference

Europe PubMed Central

1 August 2017

27

object named as

Melhem Solh

1 reference

Europe PubMed Central

1 August 2017

author name string

Ying Zhang

3

1 reference

Europe PubMed Central

1 August 2017

Andy I Chen

9

1 reference

Europe PubMed Central

1 August 2017

Yi-Bin Chen

10

1 reference

Europe PubMed Central

1 August 2017

Luciano J Costa

11

1 reference

Europe PubMed Central

1 August 2017

Mark S Hertzberg

15

1 reference

Europe PubMed Central

1 August 2017

Edward J Kanfer

19

1 reference

Europe PubMed Central

1 August 2017

David I Marks

21

1 reference

Europe PubMed Central

1 August 2017

Nishitha M Reddy

24

1 reference

Europe PubMed Central

1 August 2017

Onder Alpdogan

34

1 reference

Europe PubMed Central

1 August 2017

Robert Finke

37

1 reference

Europe PubMed Central

1 August 2017

John Gibson

39

1 reference

Europe PubMed Central

1 August 2017

Jack W Hsu

40

1 reference

Europe PubMed Central

1 August 2017

Nalini Janakiraman

41

1 reference

Europe PubMed Central

1 August 2017

Mary J Laughlin

42

1 reference

Europe PubMed Central

1 August 2017

Phil A Rowlings

46

1 reference

Europe PubMed Central

1 August 2017

Thomas C Shea

48

1 reference

Europe PubMed Central

1 August 2017

publication date

5 July 2014

1 reference

Europe PubMed Central

1 August 2017

Biology of Blood and Marrow Transplantation

1 reference

Europe PubMed Central

1 August 2017

20

1 reference

Europe PubMed Central

1 August 2017

11

1 reference

Europe PubMed Central

1 August 2017

1729-1736

1 reference

Europe PubMed Central

1 August 2017

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Controversies in BMT for lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

Quantification of the completeness of follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era

1 reference

https://pubmed.ncbi.nlm.nih.gov/25008330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25008330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25008330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25008330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BBMT.2014.06.036

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34325329&oldid=1949812591"